📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
520 announcements match the current filters (relevance ≥ 5).
Share India Securities Shareholders Approve Fundraise via FCCBs at EGM
Share India Securities Limited held its first Extraordinary General Meeting (EGM) for FY 2025-26 on December 17, 2025. The primary agenda was to seek shareholder approval for raising funds through the issuance of Foreign Currency Convertible Bonds (FCCBs). The meeting was conducted via video conferencing, and management addressed queries regarding the rationale for the capital raise. While specific amounts were not detailed in the summary, the move signals the company's intent to strengthen its capital base for future growth.
Key Highlights
Shareholders met on December 17, 2025, to approve the issuance of Foreign Currency Convertible Bonds (FCCBs).
The remote e-voting period for the resolution was held from December 14 to December 16, 2025.
The meeting was conducted efficiently, concluding in approximately 17 minutes with management responding to shareholder queries.
The fundraise is intended to support the company's strategic objectives and capital requirements for the financial year 2025-26.
👀 What to Watch
Investors should watch for the official voting results and subsequent disclosures regarding the specific size and conversion terms of the FCCBs. This capital raise could provide the necessary liquidity for expansion in the competitive brokerage and financial services sector.
Waaree Renewable Subsidiary Signs 300 MW Solar PPA with Global Tech Giant
Sunsational Power Private Limited, a wholly owned subsidiary of Waaree Renewable Technologies, has signed a long-term Power Purchase Agreement (PPA). The agreement is for a 300 MW Inter-State Transmission System (ISTS) connected solar power project. The counterparty is a leading global tech giant with significant and growing energy requirements in India. This deal provides long-term revenue visibility and strengthens the company's position in the renewable energy sector.
Key Highlights
Signed a long-term PPA for a 300 MW ISTS-connected solar power project
Agreement executed by 100% subsidiary Sunsational Power Private Limited
Counterparty is a leading global tech giant with expanding Indian operations
Project utilizes Inter-State Transmission System (ISTS) for power evacuation
👀 What to Watch
Investors should view this as a significant positive development for long-term revenue growth and order book strength. Monitor for updates on project execution timelines and specific tariff details if disclosed.
Religare Subsidiary Care Health Insurance Fined ₹1 Crore by IRDAI
Care Health Insurance Limited (CHIL), a material subsidiary of Religare Enterprises, has been penalized ₹1 crore by the IRDAI for various regulatory violations. The penalty follows an inspection conducted in 2021 which identified breaches in Third Party Administrator (TPA) health services and corporate governance guidelines. In addition to the monetary fine, the regulator issued warnings and advisories regarding financial statement preparation and policyholder interest protection. While the financial impact is limited, the regulatory focus on governance at a key subsidiary is noteworthy for shareholders.
Key Highlights
IRDAI imposed a ₹1 crore penalty on Care Health Insurance Limited (CHIL) for regulatory non-compliance.
Violations relate to TPA Health Services regulations and Corporate Governance guidelines identified during a 2021 inspection.
The regulator also issued formal warnings and advisories concerning financial reporting and policyholder protection.
The penalty is payable by CHIL and will be reflected in the consolidated financial statements of Religare Enterprises.
The order was received on December 15, 2025, following a review of the company's submissions.
👀 What to Watch
Investors should monitor for any further governance-related disclosures, as repeated regulatory friction can impact the valuation of the insurance subsidiary. The immediate financial impact of ₹1 crore is negligible relative to Religare's overall scale.
Waaree Energies Incorporates Two Step-Down Subsidiaries for Power Projects
Waaree Energies has announced the incorporation of two new step-down subsidiaries, Windora Energy Private Limited and Agni Vayu Energy Private Limited, through its wholly-owned subsidiary Waaree Forever Energies Private Limited. Both companies were incorporated on December 16, 2025, and will operate as Independent Power Producers (IPPs). These entities are specifically designed to facilitate and hold future power projects under the IPP framework. While currently having nil turnover, this move signals the company's intent to scale its power generation and project holding capacity.
Key Highlights
Incorporation of Windora Energy and Agni Vayu Energy as 100% step-down subsidiaries.
The new entities will function as Independent Power Producers (IPPs) for specific projects.
Both subsidiaries were registered on December 16, 2025, with the Registrar of Companies, Mumbai.
Waaree Forever Energies Private Limited holds 100% share capital in both new entities.
👀 What to Watch
This is a routine but positive expansion of the corporate structure to support future project execution. Investors should track the commencement of operations and project wins under these new entities.
Saregama to Acquire Stake in Bhansali Productions for INR 325 Crore
Saregama India has approved a strategic investment in Sanjay Leela Bhansali's Bhansali Productions (BPPL), starting with an initial INR 325 crore investment in Compulsory Convertible Preference Shares (CCPS). The deal includes a roadmap for Saregama to acquire a 28% to 49.9% stake by 2028 and potentially increase it to 51% by 2030. BPPL showed massive growth in FY25 with a turnover of INR 304.14 crore, compared to just INR 5.52 crore in FY24. This acquisition secures long-term music rights and strengthens Saregama's presence in high-end video content production.
Key Highlights
Initial investment of INR 325 crore for 9,960 CCPS to be completed by February 14, 2026.
Roadmap to acquire a majority 51% stake in BPPL by the end of FY2030 through phased options.
BPPL revenue surged to INR 304.14 crore in FY25 from INR 5.52 crore in FY24, driven by premium content.
Includes a Music Rights Agreement (MRA) granting Saregama ownership of all music produced by BPPL.
Strategic move to consolidate leadership in music licensing and expand into the premium video segment.
👀 What to Watch
Investors should view this as a significant strategic move that secures high-value intellectual property and premium music rights for Saregama's library. The deal aligns with Saregama's shift towards becoming a broader media powerhouse beyond just legacy music.
Saregama Announces Strategic Equity Investment in Bhansali Productions
Saregama India has entered into a strategic partnership involving a significant equity investment in Bhansali Productions, a premier film house with FY25 revenue of ₹304 crore and PAT of ₹45 crore. This deal grants Saregama exclusive rights to all future film music from the studio, eliminating competitive bidding and securing long-term market share. As part of a strategic shift, Saregama will phase out its own in-house film production over the next 1-2 years. The investment is projected to be EPS accretive by FY27, aiming to improve margins across music and video segments.
Key Highlights
Saregama secures exclusive rights to all future Bhansali Productions film music based on a pre-agreed formula.
Bhansali Productions reported strong FY25 financials with ₹304 crore Revenue and ₹45 crore PAT.
The studio has a robust pipeline of over 10 feature films planned for release over the next three years.
Saregama will exit in-house film production within 24 months to focus on high-value strategic partnerships.
The partnership is expected to be EPS accretive for Saregama by FY27.
👀 What to Watch
This is a strong strategic move that de-risks Saregama's film business while securing premium music IP. Investors should maintain a positive outlook as this secures a high-quality content pipeline for the next several years.
Saregama to Acquire Stake in Bhansali Productions for ₹325 Crore
Saregama India Limited has approved a strategic investment in Sanjay Leela Bhansali's Bhansali Productions (BPPL) for an initial consideration of ₹325 crore through Compulsory Convertible Preference Shares (CCPS). The deal includes a Music Rights Agreement, granting Saregama ownership of all music created by BPPL, and provides a clear path to majority control (51%) by 2030. BPPL showed explosive revenue growth in FY25, reaching ₹304.14 crore compared to just ₹5.52 crore in FY24, likely driven by major streaming and film releases. This acquisition significantly bolsters Saregama's video content pipeline and reinforces its leadership in music licensing.
Key Highlights
Initial investment of ₹325 crore for 9,960 CCPS to be completed by February 14, 2026
Right to increase shareholding to 28%-49.9% by 2028 and up to 51% majority stake by 2030
BPPL revenue surged to ₹304.14 crore in FY25 from ₹5.52 crore in FY24, a 55x increase
Exclusive Music Rights Agreement signed for all music content produced by Bhansali Productions
Strategic shift to expand presence in the high-margin video and long-form content segment
👀 What to Watch
Investors should look favorably on this deal as it secures high-quality intellectual property and a partnership with a top-tier filmmaker. Monitor how the project-based revenue of BPPL impacts Saregama's quarterly earnings consistency.
Waaree Energies Subsidiary Commences 1,500 MW Solar Module Production in Gujarat
Waaree Energies' wholly owned subsidiary, Sangam Solar One Private Limited, has officially commenced commercial operations at its new manufacturing facility in Samakhiali-Kutch, Gujarat. The facility features two solar module lines with a capacity of 750 MW each, totaling 1,500 MW of new annual capacity. This expansion is a significant step in scaling the company's production capabilities to meet rising renewable energy demand. Operations began on December 12, 2025, and are expected to contribute to revenue growth in the upcoming quarters.
Key Highlights
Wholly owned subsidiary Sangam Solar One Private Limited started operations on December 12, 2025.
Total new manufacturing capacity added is 1,500 MW (1.5 GW) at the Gujarat facility.
The facility consists of two production lines, each having an annual capacity of 750 MW.
The expansion strengthens Waaree Energies' position as a leading solar module manufacturer in India.
👀 What to Watch
Investors should monitor the capacity utilization rates and the impact of this 1.5 GW addition on the company's top-line growth in the next few quarters.
Hindware Home Innovation completes Hintastica asset sale to Ariston for ₹115 crore
Hindware Home Innovation Limited's joint venture, Hintastica Private Limited (HPL), has completed the sale of its manufacturing assets to Ariston Water Heating Products India Private Limited. The assets include land, buildings, plant, machinery, and equipment at Green Industrial Park, Telangana. The consideration for the sale was revised from ₹116 crore to ₹115 crore following a post-signing commercial review. The sale transaction was completed on December 11, 2025, after fulfilling all conditions precedent.
Key Highlights
Hintastica Private Limited (HPL) is a 50:50 Joint Venture.
Asset sale consideration revised to ₹115 crore.
Sale completed on 11 December, 2025.
Original sale consideration was INR 116 crore
👀 What to Watch
Investors should monitor Hindware Home Innovation's future capital allocation decisions following this asset sale. There is no immediate action needed.
Share India Securities Updates Terms for Rs 50 Crore NCD Issuance
Share India Securities has updated the terms for its proposed private placement of Non-Convertible Debentures (NCDs). The company intends to raise up to Rs 50 crore through the issuance of 5,000 secured, rated, and listed NCDs with a face value of Rs 1,00,000 each. This issuance includes a green shoe option of up to 2,500 NCDs within the total aggregate limit. The Finance Committee has also finalized the tenure of these instruments to be up to 24 months from the date of allotment.
Key Highlights
Total fundraise amount of up to Rs 50 crore via private placement of NCDs
Issuance includes a green shoe option of up to 2,500 NCDs worth Rs 25 crore
Tenure of the NCDs set at up to 24 months from the deemed date of allotment
Face value of each NCD is fixed at Rs 1,00,000
NCDs will be secured, rated, listed, and taxable instruments
👀 What to Watch
Investors should note the company's move to secure short-term funding for its financial services operations. The relatively small size of the fundraise suggests routine liquidity management rather than a major strategic shift.
Bajaj Healthcare Targets GLP-1 Market and Expands Alkaloid & Oncology Capacities
Bajaj Healthcare (BHL) is pivoting towards high-margin segments, including a new 250 kg/annum peptide plant scheduled for March 2026 targeting the GLP-1 (Semaglutide) market. The company has solidified its position as a key government partner in alkaloid extraction with capacities of 250 MT for opium gum and 2,500 MT for poppy straw. BHL is also expanding its CDMO footprint through a 30-API agreement with UK/EU clients and a dedicated oncology API plant expected by 2027. With a low debt-to-equity ratio of 0.45 and 20 manufacturing facilities, the company is well-positioned for its next phase of growth.
Key Highlights
Commissioned India's first poppy straw plant with 2,500 MTPA capacity under a Government of India contract.
Developing a 250 kg/annum peptide synthesis plant targeting anti-diabetic and weight-loss molecules by March 2026.
Entered a definitive CDMO agreement for the supply of 30 new APIs to customers in the UK and EU.
Constructing a dedicated Oncology API plant expected to be ready by 2027 to complement its existing formulation unit.
Maintains a strong balance sheet with a Debt/Equity ratio of 0.45 and zero USFDA 483 observations at its Vadodara facility.
👀 What to Watch
Investors should track the progress of the peptide plant commissioning in early 2026 as a major valuation catalyst. The company's entry into the high-growth GLP-1 and oncology segments makes it an attractive mid-cap pharma play for long-term portfolios.
Gujarat High Court Quashes GST Demand Order Against Bajaj Healthcare
Bajaj Healthcare Limited has successfully challenged a GST demand order in the Gujarat High Court. The court quashed the order originally issued on October 29, 2024, by the Joint Commissioner, Vadodara-II. This legal resolution removes a potential tax liability that the company had been contesting via a Writ Petition. Management has confirmed that this development has no negative impact on the company's financials or operations.
Key Highlights
Gujarat High Court quashed the GST demand order dated October 29, 2024, on December 6, 2025.
The company had filed a Writ Petition to challenge the demand issued by the Joint Commissioner, Vadodara-II.
Management states there is no impact on the financials, operations, or other activities of the company.
The order was accessed via the High Court's website on December 6, 2025, with physical copies pending.
This ruling effectively resolves the specific GST litigation matter in favor of the company.
👀 What to Watch
Investors should view this as a positive development as it eliminates a legal contingency and potential tax liability. No immediate action is required as the outcome strengthens the company's financial position by avoiding the contested demand.
CARE Ratings gets SEBI nod as Past Risk and Return Verification Agency (PaRRVA)
CARE Ratings Limited has received final recognition from SEBI to act as a Past Risk and Return Verification Agency (PaRRVA) under SEBI Circular dated April 4, 2025. The National Stock Exchange of India Limited (NSE) will serve as the PaRRVA Data Centre (PDC). CARE Ratings, in collaboration with NSE, will verify the risk–return metrics of Investment Advisers, Research Analysts, and Algorithmic Trading Providers. This recognition is valid until revoked or suspended by SEBI.
Key Highlights
CARE Ratings received final recognition from SEBI as PaRRVA on December 5, 2025.
SEBI Circular dated April 4, 2025, outlines the PaRRVA framework.
NSE will serve as the PaRRVA Data Centre (PDC).
CARE Ratings will verify risk-return metrics of Investment Advisers, Research Analysts, and Algorithmic Trading Providers.
👀 What to Watch
Investors should monitor CARE Ratings' performance in this new role and its impact on the company's revenue streams. Keep an eye on any further announcements regarding the implementation of the PaRRVA framework.
Religare Allots 19,85,816 Equity Shares on Warrant Conversion
Religare Enterprises Limited has allotted 19,85,816 equity shares upon conversion of warrants. The face value of each share is ₹10, with a premium of ₹225 each. The allotment was made to promoter entities following the receipt of ₹35,00,00,070, representing 75% of the balance consideration for the warrants. Post-allotment, the issued, subscribed, and paid-up equity share capital of the company increased to ₹3,32,74,04,790, consisting of 33,27,40,479 fully paid-up equity shares.
Key Highlights
Allotment of 19,85,816 equity shares upon warrant conversion.
₹35,00,00,070 received as balance consideration for warrants.
Equity share capital increased to ₹3,32,74,04,790 post allotment.
Each share has a face value of ₹10 with a premium of ₹225.
👀 What to Watch
Investors should note the increase in equity share capital and monitor the impact of the increased promoter holding on the company's future performance. Review the updated shareholding pattern for changes in promoter influence.
Waaree Energies Subsidiary Bags 288 MW Solar Module Supply Order from US Customer
Waaree Energies Limited's wholly owned subsidiary, Waaree Solar Americas, has secured a significant international order for the supply of 288 MW of solar modules. The contract is awarded by a prominent US-based developer and owner-operator of utility-scale solar and energy storage projects. The supply is scheduled to take place during the Financial Year 2026-27, providing healthy revenue visibility for the company's international operations. This order reinforces Waaree's growing presence in the competitive United States renewable energy market.
Key Highlights
Subsidiary Waaree Solar Americas to supply 288 MW of solar modules to a US-based utility-scale developer.
The order is scheduled for execution and supply during the Financial Year 2026-27.
The contract is with an international, non-related party, ensuring no conflict of interest.
Strengthens the company's international order book and market position in the North American solar sector.
👀 What to Watch
Investors should view this as a positive development for long-term revenue growth; however, they should monitor the company's ability to maintain margins amidst global supply chain dynamics.
RS Software Board Meeting Outcome: Financial Results for Sep 2025
R. S. Software (India) Limited's board meeting on November 05, 2025, approved the audited standalone and consolidated financial results for the period ending September 30, 2025. The meeting, which commenced at 11:30 AM and concluded at 12:40 PM, also included a review of the Auditor’s Reports. The company has confirmed submitting the Auditor’s Reports with Unmodified Opinions and the Financial Results as per Schedule III of the Companies Act 2013. Investors should review the detailed financial results for insights into the company's performance.
Key Highlights
Board meeting held on November 05, 2025
Meeting started at 11:30 AM and concluded at 12:40 PM
Approved Audited Standalone and Consolidated Financial Results for the period ending 30th September 2025
Auditor’s Reports with Unmodified Opinions submitted
👀 What to Watch
Review the company's financial results for the period ending September 30, 2025, to understand the company's financial health. Monitor future announcements for further updates.
Waaree Energies faces ₹85.09 Lakh penalty for GST on rooftop solar panel subsidies
Waaree Energies Limited has received an order from the Assistant Commissioner, Central GST & Central Excise Division-IV, Surat, imposing a penalty of ₹85,09,810. The penalty is under section 74(1) of the CGST Act, 2017 read with 74(1) of the Gujarat GST Act, 2017. It relates to GST on subsidy amounts for rooftop solar panel systems for residential consumers. The company is planning to appeal the order.
Key Highlights
Penalty of ₹85,09,810 imposed by Assistant Commissioner, Central GST & Central Excise Division-IV, Surat.
Penalty under section 74(1) of the CGST Act, 2017 and Gujarat GST Act, 2017.
Concerns GST amount on subsidy for Rooftop Solar Panel systems.
Intimation received on December 01, 2025 at 11:18 A.M. (IST).
👀 What to Watch
Investors should monitor the outcome of the appeal process. While the company believes the demand is not tenable, an unfavorable outcome could impact future profitability.
MT Educare Reports ₹32.33 Cr Debt Default; Remains Under Insolvency Process
MT Educare Limited has reported a total default of ₹32.33 crore in principal and interest payments to Prudent ARC and Axis Bank. The company has been under the Corporate Insolvency Resolution Process (CIRP) since December 16, 2022, following an NCLT order. Beyond direct borrowings, the company faces invoked corporate guarantees totaling approximately ₹23.99 crore. The resolution process is currently managed by Resolution Professional Arihant Nenawati, with claims verification still in progress.
Key Highlights
Total outstanding borrowings from banks and financial institutions amount to ₹32.33 crore.
Default includes ₹20.19 crore to Prudent ARC and ₹12.16 crore to Axis Bank (Principal + Interest).
Invoked corporate guarantees include ₹7.3 crore for Sri Gayatri Education Society and ₹16.69 crore for Lakshya Forum.
A ₹49.72 crore claim by Shamrao Vithal Co-op Bank was rejected and is currently under appeal at the NCLAT.
The company has been in default since March 2021 and remains under the CIRP framework since late 2022.
👀 What to Watch
Investors should be extremely cautious as the company is undergoing insolvency proceedings, which typically results in significant equity dilution or total loss for shareholders. Monitor NCLT and NCLAT updates regarding the approval of any resolution plan.
Thyrocare Allots 10.61 Crore Bonus Equity Shares in 2:1 Ratio
Thyrocare Technologies has successfully allotted 10,61,07,794 bonus equity shares to eligible shareholders as of the record date, November 28, 2025. The bonus issue was executed in a 2:1 ratio, meaning shareholders received two new shares for every one share held. This corporate action has increased the company's total paid-up share capital from Rs. 53.05 crore to Rs. 159.16 crore. The total number of outstanding equity shares has tripled to 15,91,61,691 shares.
Key Highlights
Allotment of 10,61,07,794 fully paid-up bonus equity shares of Rs. 10 each
Bonus ratio of 2:1 implemented for all eligible members as of November 28, 2025
Total paid-up share capital increased from 5,30,53,897 to 15,91,61,691 equity shares
Post-bonus paid-up capital value stands at Rs. 159,16,16,910
New shares rank pari-passu in all respects with existing equity shares
👀 What to Watch
Investors should account for the tripled share count in their portfolios and note that the stock price has adjusted to reflect the 2:1 bonus. No further action is required as the allotment is now complete.
Thyrocare Allots 10,61,07,794 Bonus Equity Shares
Thyrocare Technologies Limited has announced the allotment of 10,61,07,794 equity shares as bonus shares in the proportion of 2:1. This means shareholders received 2 new shares for every 1 existing share held. The face value of each share is ₹10. Consequently, the paid-up share capital has increased from ₹53,05,38,970 to ₹1,59,16,16,910. The bonus shares rank equally with existing shares.
Key Highlights
Allotted 10,61,07,794 bonus equity shares
Bonus issue ratio is 2:1
Face value of each share is ₹10
Paid-up share capital increased to ₹1,59,16,16,910 post bonus issue
👀 What to Watch
Existing shareholders should see the bonus shares reflected in their demat accounts. Monitor the stock's performance post-bonus issue to assess its impact on the share price.
